With New Alzheimers Data, Biogen Refines Plans For Big Trial
Summary
These results are the latest tidbits from the Phase 1b study first disclosed in March, although Biogen executives began telegraphing positive signals from the trial late last year.As the dose ramped up, aducanumab did better at breaking up amyloid plaques, the telltale protein clumps that build up in the brains of Alzheimer’s patients.“This is a [study size] where a patient or two can move numbers pretty easily, so it’s important to look at the totality of the data,” Biogen spokesman Todd Cooper says.Those questions still don’t have definitive answers, but Biogen breathed new life into the amyloid hypothesis this past year with its Phase 1b aducanumab study.The majority of the data, presented at a March medical meeting in France, added billions of dollars to Biogen’s market cap and … Next Page »